November 8th 2024
Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.
May 3rd 2024
Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.
March 11th 2024
Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.
March 4th 2024
Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.
February 26th 2024
This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.
Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.
February 19th 2024
Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.
GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice
February 16th 2024
Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.
February 15th 2024
Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.
February 9th 2024
Summarizes the main points and benefits of multidisciplinary prostate cancer care.
February 2nd 2024
Covers key factors in deciding on radiation treatment.
Discusses treatment options for advanced metastatic disease.
January 30th 2024
Looks at approaches for isolated lymph node involvement.
Examines the considerations for operating on older prostate cancer patients.
January 19th 2024
Reviews a case of a patient with high PSA but no other symptoms.
Explains the importance of respect and collaboration between care providers.
January 12th 2024
Focuses on patients being active participants in their treatment choices.
Highlights the advantages of various providers working together for patient care.